It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. On average, Leonard trades about 87,058 units every 129 days since 2003. The largest trade he's ever made was exercising 500,000 units of Regeneron Pharmaceuticals stock on 14 February 2012 worth over $8,110,000. Leonard Schleifer’s income source is mostly from being a successful . Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. So, how much is Leonard Schleifer worth at the age of 67 years old? With over 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. 6. Most recently he exercised 312,500 units of REGN stock worth … Dr. Leonard S. Schleifer M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. Net worth: $2.2 billion Wealth increase during pandemic: $300 million Leonard Schleifer is the billionaire co-founder of Regeneron Pharmaceuticals, a New York-based biotech firm that is currently testing whether its arthritis drug is effective against COVID-19. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. It was previously run by Westinghouse, then, more recently, Intel. Net worth: $2.2 billion Wealth increase during pandemic: $300 million. Eylea prevented leaky blood vessels in the eye from causing blindness. Leonard Schleifer was bornon 1953 in Tarrytown, New York, United States, is CEO and Founder, Regeneron Pharmaceuticals. In 2014 Eylea grossed $1.735 billion. The most recent stock trade was executed by Joseph L Goldstein on 5 October 2020, trading 9,212 units of REGN stock currently worth $4,790,332. Schleifer, who has most of his fortune tied up in Regeneron, grew up in Queens. Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. Noticing that the biotechnology company Genentech was conducting state-of-the-art research but not on diseases of the nervous system, he determined to get into the biotechnology Business. He implemented two strategic changes: only invest in drugs in which the biology of the disorder is fully understood; and do not underestimate the importance of human testing to ensure that what works in the laboratory will also work in the real world. Leonard Schleifer is the billionaire co-founder of Regeneron Pharmaceuticals, a New York-based biotech firm that is currently testing whether its arthritis drug is effective against COVID-19. Last updated: 1 October 2020 at 11:00am EST. Net Worth and Insider Trades. It was a failure as was their second drug to treat obesity. With over 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded Regeneron Pharmaceuticals. Regeneron manufactured a blockbuster drug to treat "wet" … Leonard Schleifer—His net worth is $2.2 billion, a rise of 11% due to the pandemic. As the President, Chief Executive Officer, and Director of Regeneron Pharmaceuticals, the total compensation of Leonard Schleifer at Regeneron Pharmaceuticals is $21,455,100. There are 6 older and 12 younger executives at Regeneron Pharmaceuticals. Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker. . The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. Insiders are officers, directors, or significant investors in a company. Thereafter, they invited the former Merck & Co. CEO Roy Vagelos to be the chairman of their company to help turn the company around. The estimated Net Worth of Leonard S Schleifer is at least $535 Million dollars as of 11 May 2020. Schleifer followed his father's footsteps to Cornell and then got an M.D.-PhD degree at the University of Virginia, training with future Nobel Laureate Alfred Gilman. If the drug proves effective it would be a boon for the company but Schleifer is already seeing personal gain. Over the last 18 years, insiders at Regeneron Pharmaceuticals have traded over $12,521,007,046 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. The estimated Net Worth of Leonard S Schleifer is at least $542 Million dollars as of 11 May 2020. It is illegal for insiders to make trades in their companies based … Leonard has made over 35 trades of the Regeneron Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a Billionaire. Leonard has made over 35 trades of the Regeneron Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC.